Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV)
BackgroundHeart failure (HF) is a global problem with a high mortality rate, and advanced HF (AHF) represents the stage with the highest morbidity and mortality. We have no local data on this population and its treatment. The aim of this study will be to determine the epidemiological, clinical, ther...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.896821/full |
| _version_ | 1818007412744912896 |
|---|---|
| author | Manuel Chacón-Diaz Manuel Chacón-Diaz Rocío Laymito Quispe Akram Hernández-Vásquez Rodrigo Vargas-Fernández |
| author_facet | Manuel Chacón-Diaz Manuel Chacón-Diaz Rocío Laymito Quispe Akram Hernández-Vásquez Rodrigo Vargas-Fernández |
| author_sort | Manuel Chacón-Diaz |
| collection | DOAJ |
| description | BackgroundHeart failure (HF) is a global problem with a high mortality rate, and advanced HF (AHF) represents the stage with the highest morbidity and mortality. We have no local data on this population and its treatment. The aim of this study will be to determine the epidemiological, clinical, therapeutic, and annual survival characteristics of patients diagnosed with AHF treated in hospitals with HF units in the city of Lima, Peru.Methods and AnalysisAn observational, prospective, multicenter study will be conducted with evaluation at baseline and follow-up at 1, 3, 6, and 12 months after study entry. Patients over 18 years of age with AHF seen in referral health facilities in metropolitan Lima will be included. The cumulative mortality during follow-up will be estimated by the Kaplan-Meier method, and Cox regression models will calculate hazard ratios (HRs) and 95% confidence intervals (CI). Likewise, risk ratio (RR) and 95% CI will be estimated using generalized linear models with binomial family and log link function. This study was approved by the Ethics and Research Committee of the National Cardiovascular Institute (Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo”—INCOR [in Spanish]; Approval report 46/2021-CEI).DiscussionIn Peru, there are no scientific data on the epidemiology of AHF in the population. This means that physicians are not adequately trained in the characteristics of the Peruvian population to identify patients who could be candidates for advanced therapies and to recognize the optimal time to refer these patients to more complex HF units. This study will be the first to examine the clinical-epidemiological characteristics of AHF in Peru with a follow-up of 1 year after the event and will provide relevant information on these observable characteristics for the management of high-complexity patients. |
| first_indexed | 2024-04-14T05:16:22Z |
| format | Article |
| id | doaj.art-333fdce7ff4c4e2582cb9f542eddbc33 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-14T05:16:22Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-333fdce7ff4c4e2582cb9f542eddbc332022-12-22T02:10:22ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-05-01910.3389/fcvm.2022.896821896821Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV)Manuel Chacón-Diaz0Manuel Chacón-Diaz1Rocío Laymito Quispe2Akram Hernández-Vásquez3Rodrigo Vargas-Fernández4Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, PeruInstituto Nacional Cardiovascular, EsSalud, Lima, PeruHospital Nacional Alberto Sabogal Sologuren, Lima, PeruCentro de Excelencia en Investigaciones Económicas y Sociales en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, PeruFacultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, PeruBackgroundHeart failure (HF) is a global problem with a high mortality rate, and advanced HF (AHF) represents the stage with the highest morbidity and mortality. We have no local data on this population and its treatment. The aim of this study will be to determine the epidemiological, clinical, therapeutic, and annual survival characteristics of patients diagnosed with AHF treated in hospitals with HF units in the city of Lima, Peru.Methods and AnalysisAn observational, prospective, multicenter study will be conducted with evaluation at baseline and follow-up at 1, 3, 6, and 12 months after study entry. Patients over 18 years of age with AHF seen in referral health facilities in metropolitan Lima will be included. The cumulative mortality during follow-up will be estimated by the Kaplan-Meier method, and Cox regression models will calculate hazard ratios (HRs) and 95% confidence intervals (CI). Likewise, risk ratio (RR) and 95% CI will be estimated using generalized linear models with binomial family and log link function. This study was approved by the Ethics and Research Committee of the National Cardiovascular Institute (Instituto Nacional Cardiovascular “Carlos Alberto Peschiera Carrillo”—INCOR [in Spanish]; Approval report 46/2021-CEI).DiscussionIn Peru, there are no scientific data on the epidemiology of AHF in the population. This means that physicians are not adequately trained in the characteristics of the Peruvian population to identify patients who could be candidates for advanced therapies and to recognize the optimal time to refer these patients to more complex HF units. This study will be the first to examine the clinical-epidemiological characteristics of AHF in Peru with a follow-up of 1 year after the event and will provide relevant information on these observable characteristics for the management of high-complexity patients.https://www.frontiersin.org/articles/10.3389/fcvm.2022.896821/fullheart failureheart disease risk factorprospective study designPerucardiovascular diseases |
| spellingShingle | Manuel Chacón-Diaz Manuel Chacón-Diaz Rocío Laymito Quispe Akram Hernández-Vásquez Rodrigo Vargas-Fernández Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) Frontiers in Cardiovascular Medicine heart failure heart disease risk factor prospective study design Peru cardiovascular diseases |
| title | Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) |
| title_full | Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) |
| title_fullStr | Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) |
| title_full_unstemmed | Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) |
| title_short | Study Protocol for the Peruvian Registry of Advanced Heart Failure (REPICAV) |
| title_sort | study protocol for the peruvian registry of advanced heart failure repicav |
| topic | heart failure heart disease risk factor prospective study design Peru cardiovascular diseases |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.896821/full |
| work_keys_str_mv | AT manuelchacondiaz studyprotocolfortheperuvianregistryofadvancedheartfailurerepicav AT manuelchacondiaz studyprotocolfortheperuvianregistryofadvancedheartfailurerepicav AT rociolaymitoquispe studyprotocolfortheperuvianregistryofadvancedheartfailurerepicav AT akramhernandezvasquez studyprotocolfortheperuvianregistryofadvancedheartfailurerepicav AT rodrigovargasfernandez studyprotocolfortheperuvianregistryofadvancedheartfailurerepicav |